Clear cell RCC—therapy subsequent to progression after first-line therapy
Preferred	Cabozantinib Nivolumab Ipilimumab+nivolumab
Other recommended	Axitinib Lenvatinib+everolimus Everolimus Pazopanib Sunitinib
Useful in certain circumstances	Bevacizumab Sorafenib High-dose interleukin-2—selected patients Temsirolimus